Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 7/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744669 | 0.85 | HCAR2 (0.47) | HCRTR1HCRTR2HRH4NAAAHDAC3 | |
| SCHEMBL23744676 | 0.85 | HCAR2 (0.47) | HCRTR1HCRTR2HRH4NAAAHDAC3 | |
| SCHEMBL23744668 | 0.83 | HCAR2 (0.48) | GRM1TRPV1HCRTR1HCRTR2HDAC3 | |
| SCHEMBL23744645 | 0.80 | MEN1 (0.43) | GRM1HCRTR1HCRTR2PARP1PARP2 | |
| SCHEMBL26089815 | 0.80 | HCAR2 (0.50) | HCRTR1HCRTR2HRH4NAAAHDAC3 | |
| SCHEMBL23727541 | 0.80 | HCAR2 (0.50) | HCRTR1HCRTR2HRH4NAAAHDAC3 | |
| SCHEMBL26087425 | 0.76 | HCAR2 (0.52) | HCRTR1HCRTR2PARP1PARP2HDAC3 | |
| SCHEMBL23744797 | 0.75 | ACVR1 (0.47) | HRH4HDAC3HDAC2 | |
| SCHEMBL9957907 | 0.73 | HCRTR1 (0.44) | HCRTR1HCRTR2HDAC3HDAC2 | |
| SCHEMBL23744193 | 0.73 | MEN1 (0.43) | HCRTR1HCRTR2HRH4HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | GRM1 68/4885TRPV1 164/4885HCRTR1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.